Target intelligence / Profile preview

Puumala virus envelope glycoproteins Gn and Gc (Gn/Gc)

Target
Gn/Gc
Molecular classification
Viral envelope glycoprotein, Viral envelope glycoprotein complex, Class II viral fusion protein, Other
01

Overview

**Puumala virus envelope glycoproteins Gn and Gc** are essential viral surface proteins encoded by the medium (M) segment of hantavirus genomes, including Puumala virus, a significant cause of hemorrhagic fever with renal syndrome in Europe. Together, Gn and Gc form spike complexes on the viral envelope, crucial for virion assembly, surface architecture, and facilitating viral cell entry. Gn is positioned membrane-distal and is involved in viral attachment, displaying pronounced antigenic diversity due to immune selection. Gc is a class II fusion protein, mediating membrane fusion between the viral envelope and host endosomal membranes, triggered by low pH, which is essential for viral entry. High-resolution structural studies have revealed their oligomeric organization and conformational changes. Both Gn and Gc are focal points for antiviral strategies, with neutralizing antibodies targeting them by blocking binding, fusion, or conformational rearrangements. Despite their high sequence diversity and structural flexibility posing challenges for vaccine and antibody design, they represent important targets for antiviral antibody responses and potential vaccine development.

Other names
Glycoprotein NHantavirus GnPUUV GnGlycoprotein CHantavirus GcPUUV Gc
02

Mechanism of action

Antibody-mediated neutralization (prevention of virus binding/fusion by steric hindrance or conformational blockade); Inhibition of pH-dependent membrane fusion through antibody blockade or fusion inhibitor binding.

03

Biological functions

Viral attachmentViral assemblyHost immune evasionStructure formation of virion spike complexMembrane fusion (viral entry)Spike complex formation
04

Disease associations

Infection (specifically hemorrhagic fever with renal syndrome due to Puumala virus)Other
05

Safety considerations

High sequence diversity leads to antigenic variability and potential immune evasion; pH-triggered conformational changes and structural flexibility complicate inhibitor/vaccine design; possible off-target immune effects
06

Interacting drugs

No approved drugs; experimental neutralizing antibodies and entry inhibitor research in progress
07

Biomarkers

None established; serological detection of anti-Gn and anti-Gc antibodies used in infection diagnosis and humoral response profiling

Beyond the preview

Go deeper on Puumala virus envelope glycoproteins Gn and Gc (Gn/Gc).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Puumala virus envelope glycoproteins Gn and Gc (Gn/Gc).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call